Premium
Neurochemical dementia diagnostics: State of the art and research perspectives
Author(s) -
Lewczuk Piotr,
Wiltfang Jens
Publication year - 2008
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200700703
Subject(s) - dementia , neurochemical , neuroscience , disease , differential diagnosis , medicine , biomarker , cognitive impairment , psychology , bioinformatics , pathology , biology , biochemistry
The aim of this review is to present current state of the art on the field of routine neurochemical dementia diagnostics (NDD) with a focus on cerebrospinal fluid (CSF) biomarkers: amyloid β peptides, tau protein, and its phosphorylated form (pTau). After several years of experience, it is reasonably to postulate that CSF biomarkers analysis is an increasingly important tool within the early and differential diagnosis of dementia syndromes. Actual research activities are briefly discussed, too, including: (i) possibilities and limitations of the diagnosis of incipient Alzheimer's disease in preclinical stages ( e.g ., mild cognitive impairment), (ii) the role of multiplexing technologies in dementia biomarkers research, (iii) the role of biomarkers in differential diagnosis of dementia syndromes, (iv) approaches to improve analytical performance of available methods, and (v) research activities to identify dementia biomarkers in blood.